Mechanistically, we found that treatment of Exo/ASO-TNF or Exo/2DG potentially alleviated the progression of experimental NASH by up-regulating the expression of Sod1 (Fig. S12). The gene discussed is SOD1; the disease is metabolic dysfunction-associated steatohepatitis.